カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の水痘弱毒生ワクチン接種市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Varicella Attenuated Live Vaccination Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19686）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19686
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：97
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の水痘弱毒生ワクチン接種市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

水痘弱毒生ワクチン接種市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の水痘弱毒生ワクチン接種の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

水痘弱毒生ワクチン接種市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・一価ワクチン、混合ワクチン

用途別セグメントは次のように区分されます。
・こども、大人

世界の水痘弱毒生ワクチン接種市場の主要な市場プレーヤーは以下のとおりです。
・Merck、BCHT、Shanghai Institute、GSK、Keygen、Green Cross、Biken、Shanghai Rongsheng Biotech、Changsheng

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、水痘弱毒生ワクチン接種製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な水痘弱毒生ワクチン接種メーカーの企業概要、2019年～2022年までの水痘弱毒生ワクチン接種の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な水痘弱毒生ワクチン接種メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別水痘弱毒生ワクチン接種の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの水痘弱毒生ワクチン接種の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での水痘弱毒生ワクチン接種市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および水痘弱毒生ワクチン接種の産業チェーンを掲載しています。
・第13、14、15章では、水痘弱毒生ワクチン接種の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 水痘弱毒生ワクチン接種の概要
- 種類別分析（2017年vs2021年vs2028年）：一価ワクチン、混合ワクチン
- 用途別分析（2017年vs2021年vs2028年）：こども、大人
- 世界の水痘弱毒生ワクチン接種市場規模・予測
- 世界の水痘弱毒生ワクチン接種生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Merck、BCHT、Shanghai Institute、GSK、Keygen、Green Cross、Biken、Shanghai Rongsheng Biotech、Changsheng
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：一価ワクチン、混合ワクチン
・用途別分析2017年-2028年：こども、大人
・水痘弱毒生ワクチン接種の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・水痘弱毒生ワクチン接種のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・水痘弱毒生ワクチン接種のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・水痘弱毒生ワクチン接種の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・水痘弱毒生ワクチン接種の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Varicella Attenuated Live Vaccination market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Varicella Attenuated Live Vaccination market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Children accounting for % of the Varicella Attenuated Live Vaccination global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monovalent Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Varicella Attenuated Live Vaccination include Merck, BCHT, Shanghai Institute, GSK, and Keygen, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Varicella Attenuated Live Vaccination market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monovalent Vaccine
Combination Vaccine
Market segment by Application can be divided into
Children
Adults
The key market players for global Varicella Attenuated Live Vaccination market are listed below:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Varicella Attenuated Live Vaccination product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Varicella Attenuated Live Vaccination, with price, sales, revenue and global market share of Varicella Attenuated Live Vaccination from 2019 to 2022.
Chapter 3, the Varicella Attenuated Live Vaccination competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Varicella Attenuated Live Vaccination breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Varicella Attenuated Live Vaccination market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Varicella Attenuated Live Vaccination.
Chapter 13, 14, and 15, to describe Varicella Attenuated Live Vaccination sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Varicella Attenuated Live Vaccination Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Varicella Attenuated Live Vaccination Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Varicella Attenuated Live Vaccination Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Children
1.3.3 Adults
1.4 Global Varicella Attenuated Live Vaccination Market Size & Forecast
1.4.1 Global Varicella Attenuated Live Vaccination Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Varicella Attenuated Live Vaccination Sales in Volume (2017-2028)
1.4.3 Global Varicella Attenuated Live Vaccination Price (2017-2028)
1.5 Global Varicella Attenuated Live Vaccination Production Capacity Analysis
1.5.1 Global Varicella Attenuated Live Vaccination Total Production Capacity (2017-2028)
1.5.2 Global Varicella Attenuated Live Vaccination Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Varicella Attenuated Live Vaccination Market Drivers
1.6.2 Varicella Attenuated Live Vaccination Market Restraints
1.6.3 Varicella Attenuated Live Vaccination Trends Analysis
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Varicella Attenuated Live Vaccination Product and Services
2.1.4 Merck Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 BCHT
2.2.1 BCHT Details
2.2.2 BCHT Major Business
2.2.3 BCHT Varicella Attenuated Live Vaccination Product and Services
2.2.4 BCHT Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Shanghai Institute
2.3.1 Shanghai Institute Details
2.3.2 Shanghai Institute Major Business
2.3.3 Shanghai Institute Varicella Attenuated Live Vaccination Product and Services
2.3.4 Shanghai Institute Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Varicella Attenuated Live Vaccination Product and Services
2.4.4 GSK Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Keygen
2.5.1 Keygen Details
2.5.2 Keygen Major Business
2.5.3 Keygen Varicella Attenuated Live Vaccination Product and Services
2.5.4 Keygen Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Green Cross
2.6.1 Green Cross Details
2.6.2 Green Cross Major Business
2.6.3 Green Cross Varicella Attenuated Live Vaccination Product and Services
2.6.4 Green Cross Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Biken
2.7.1 Biken Details
2.7.2 Biken Major Business
2.7.3 Biken Varicella Attenuated Live Vaccination Product and Services
2.7.4 Biken Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Shanghai Rongsheng Biotech
2.8.1 Shanghai Rongsheng Biotech Details
2.8.2 Shanghai Rongsheng Biotech Major Business
2.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Product and Services
2.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Changsheng
2.9.1 Changsheng Details
2.9.2 Changsheng Major Business
2.9.3 Changsheng Varicella Attenuated Live Vaccination Product and Services
2.9.4 Changsheng Varicella Attenuated Live Vaccination Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Varicella Attenuated Live Vaccination Breakdown Data by Manufacturer
3.1 Global Varicella Attenuated Live Vaccination Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Varicella Attenuated Live Vaccination Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Varicella Attenuated Live Vaccination
3.4 Market Concentration Rate
3.4.1 Top 3 Varicella Attenuated Live Vaccination Manufacturer Market Share in 2021
3.4.2 Top 6 Varicella Attenuated Live Vaccination Manufacturer Market Share in 2021
3.5 Global Varicella Attenuated Live Vaccination Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Varicella Attenuated Live Vaccination Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Varicella Attenuated Live Vaccination Market Size by Region
4.1.1 Global Varicella Attenuated Live Vaccination Sales in Volume by Region (2017-2028)
4.1.2 Global Varicella Attenuated Live Vaccination Revenue by Region (2017-2028)
4.2 North America Varicella Attenuated Live Vaccination Revenue (2017-2028)
4.3 Europe Varicella Attenuated Live Vaccination Revenue (2017-2028)
4.4 Asia-Pacific Varicella Attenuated Live Vaccination Revenue (2017-2028)
4.5 South America Varicella Attenuated Live Vaccination Revenue (2017-2028)
4.6 Middle East and Africa Varicella Attenuated Live Vaccination Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Varicella Attenuated Live Vaccination Sales in Volume by Type (2017-2028)
5.2 Global Varicella Attenuated Live Vaccination Revenue by Type (2017-2028)
5.3 Global Varicella Attenuated Live Vaccination Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Varicella Attenuated Live Vaccination Sales in Volume by Application (2017-2028)
6.2 Global Varicella Attenuated Live Vaccination Revenue by Application (2017-2028)
6.3 Global Varicella Attenuated Live Vaccination Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Varicella Attenuated Live Vaccination Sales by Type (2017-2028)
7.2 North America Varicella Attenuated Live Vaccination Sales by Application (2017-2028)
7.3 North America Varicella Attenuated Live Vaccination Market Size by Country
7.3.1 North America Varicella Attenuated Live Vaccination Sales in Volume by Country (2017-2028)
7.3.2 North America Varicella Attenuated Live Vaccination Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Varicella Attenuated Live Vaccination Sales by Type (2017-2028)
8.2 Europe Varicella Attenuated Live Vaccination Sales by Application (2017-2028)
8.3 Europe Varicella Attenuated Live Vaccination Market Size by Country
8.3.1 Europe Varicella Attenuated Live Vaccination Sales in Volume by Country (2017-2028)
8.3.2 Europe Varicella Attenuated Live Vaccination Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Varicella Attenuated Live Vaccination Sales by Type (2017-2028)
9.2 Asia-Pacific Varicella Attenuated Live Vaccination Sales by Application (2017-2028)
9.3 Asia-Pacific Varicella Attenuated Live Vaccination Market Size by Region
9.3.1 Asia-Pacific Varicella Attenuated Live Vaccination Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Varicella Attenuated Live Vaccination Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Varicella Attenuated Live Vaccination Sales by Type (2017-2028)
10.2 South America Varicella Attenuated Live Vaccination Sales by Application (2017-2028)
10.3 South America Varicella Attenuated Live Vaccination Market Size by Country
10.3.1 South America Varicella Attenuated Live Vaccination Sales in Volume by Country (2017-2028)
10.3.2 South America Varicella Attenuated Live Vaccination Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Varicella Attenuated Live Vaccination Sales by Type (2017-2028)
11.2 Middle East & Africa Varicella Attenuated Live Vaccination Sales by Application (2017-2028)
11.3 Middle East & Africa Varicella Attenuated Live Vaccination Market Size by Country
11.3.1 Middle East & Africa Varicella Attenuated Live Vaccination Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Varicella Attenuated Live Vaccination and Key Manufacturers
12.2 Manufacturing Costs Percentage of Varicella Attenuated Live Vaccination
12.3 Varicella Attenuated Live Vaccination Production Process
12.4 Varicella Attenuated Live Vaccination Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Varicella Attenuated Live Vaccination Typical Distributors
13.3 Varicella Attenuated Live Vaccination Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Varicella Attenuated Live Vaccination Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Varicella Attenuated Live Vaccination Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Merck Basic Information, Manufacturing Base and Competitors
Table 4. Merck Major Business
Table 5. Merck Varicella Attenuated Live Vaccination Product and Services
Table 6. Merck Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. BCHT Basic Information, Manufacturing Base and Competitors
Table 8. BCHT Major Business
Table 9. BCHT Varicella Attenuated Live Vaccination Product and Services
Table 10. BCHT Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Shanghai Institute Basic Information, Manufacturing Base and Competitors
Table 12. Shanghai Institute Major Business
Table 13. Shanghai Institute Varicella Attenuated Live Vaccination Product and Services
Table 14. Shanghai Institute Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. GSK Basic Information, Manufacturing Base and Competitors
Table 16. GSK Major Business
Table 17. GSK Varicella Attenuated Live Vaccination Product and Services
Table 18. GSK Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Keygen Basic Information, Manufacturing Base and Competitors
Table 20. Keygen Major Business
Table 21. Keygen Varicella Attenuated Live Vaccination Product and Services
Table 22. Keygen Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Green Cross Basic Information, Manufacturing Base and Competitors
Table 24. Green Cross Major Business
Table 25. Green Cross Varicella Attenuated Live Vaccination Product and Services
Table 26. Green Cross Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Biken Basic Information, Manufacturing Base and Competitors
Table 28. Biken Major Business
Table 29. Biken Varicella Attenuated Live Vaccination Product and Services
Table 30. Biken Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Shanghai Rongsheng Biotech Basic Information, Manufacturing Base and Competitors
Table 32. Shanghai Rongsheng Biotech Major Business
Table 33. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Product and Services
Table 34. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Changsheng Basic Information, Manufacturing Base and Competitors
Table 36. Changsheng Major Business
Table 37. Changsheng Varicella Attenuated Live Vaccination Product and Services
Table 38. Changsheng Varicella Attenuated Live Vaccination Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Varicella Attenuated Live Vaccination Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Units)
Table 40. Global Varicella Attenuated Live Vaccination Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Varicella Attenuated Live Vaccination, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Varicella Attenuated Live Vaccination Production Capacity by Company, (Units): 2020 VS 2021
Table 43. Head Office and Varicella Attenuated Live Vaccination Production Site of Key Manufacturer
Table 44. Varicella Attenuated Live Vaccination New Entrant and Capacity Expansion Plans
Table 45. Varicella Attenuated Live Vaccination Mergers & Acquisitions in the Past Five Years
Table 46. Global Varicella Attenuated Live Vaccination Sales by Region (2017-2022) & (Units)
Table 47. Global Varicella Attenuated Live Vaccination Sales by Region (2023-2028) & (Units)
Table 48. Global Varicella Attenuated Live Vaccination Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Varicella Attenuated Live Vaccination Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 51. Global Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 52. Global Varicella Attenuated Live Vaccination Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Varicella Attenuated Live Vaccination Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Varicella Attenuated Live Vaccination Price by Type (2017-2022) & (US$/Unit)
Table 55. Global Varicella Attenuated Live Vaccination Price by Type (2023-2028) & (US$/Unit)
Table 56. Global Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 57. Global Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 58. Global Varicella Attenuated Live Vaccination Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Varicella Attenuated Live Vaccination Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Varicella Attenuated Live Vaccination Price by Application (2017-2022) & (US$/Unit)
Table 61. Global Varicella Attenuated Live Vaccination Price by Application (2023-2028) & (US$/Unit)
Table 62. North America Varicella Attenuated Live Vaccination Sales by Country (2017-2022) & (Units)
Table 63. North America Varicella Attenuated Live Vaccination Sales by Country (2023-2028) & (Units)
Table 64. North America Varicella Attenuated Live Vaccination Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Varicella Attenuated Live Vaccination Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 67. North America Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 68. North America Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 69. North America Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 70. Europe Varicella Attenuated Live Vaccination Sales by Country (2017-2022) & (Units)
Table 71. Europe Varicella Attenuated Live Vaccination Sales by Country (2023-2028) & (Units)
Table 72. Europe Varicella Attenuated Live Vaccination Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Varicella Attenuated Live Vaccination Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 75. Europe Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 76. Europe Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 77. Europe Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 78. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Region (2017-2022) & (Units)
Table 79. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Region (2023-2028) & (Units)
Table 80. Asia-Pacific Varicella Attenuated Live Vaccination Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Varicella Attenuated Live Vaccination Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 83. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 84. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 85. Asia-Pacific Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 86. South America Varicella Attenuated Live Vaccination Sales by Country (2017-2022) & (Units)
Table 87. South America Varicella Attenuated Live Vaccination Sales by Country (2023-2028) & (Units)
Table 88. South America Varicella Attenuated Live Vaccination Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Varicella Attenuated Live Vaccination Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 91. South America Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 92. South America Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 93. South America Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 94. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Region (2017-2022) & (Units)
Table 95. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Region (2023-2028) & (Units)
Table 96. Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Type (2017-2022) & (Units)
Table 99. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Type (2023-2028) & (Units)
Table 100. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Application (2017-2022) & (Units)
Table 101. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Application (2023-2028) & (Units)
Table 102. Varicella Attenuated Live Vaccination Raw Material
Table 103. Key Manufacturers of Varicella Attenuated Live Vaccination Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Varicella Attenuated Live Vaccination Typical Distributors
Table 107. Varicella Attenuated Live Vaccination Typical Customers
List of Figures
Figure 1. Varicella Attenuated Live Vaccination Picture
Figure 2. Global Varicella Attenuated Live Vaccination Revenue Market Share by Type in 2021
Figure 3. Monovalent Vaccine
Figure 4. Combination Vaccine
Figure 5. Global Varicella Attenuated Live Vaccination Revenue Market Share by Application in 2021
Figure 6. Children
Figure 7. Adults
Figure 8. Global Varicella Attenuated Live Vaccination Revenue, (USD Million) & (Units): 2017 & 2021 & 2028
Figure 9. Global Varicella Attenuated Live Vaccination Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Varicella Attenuated Live Vaccination Sales (2017-2028) & (Units)
Figure 11. Global Varicella Attenuated Live Vaccination Price (2017-2028) & (US$/Unit)
Figure 12. Global Varicella Attenuated Live Vaccination Production Capacity (2017-2028) & (Units)
Figure 13. Global Varicella Attenuated Live Vaccination Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Varicella Attenuated Live Vaccination Market Drivers
Figure 15. Varicella Attenuated Live Vaccination Market Restraints
Figure 16. Varicella Attenuated Live Vaccination Market Trends
Figure 17. Global Varicella Attenuated Live Vaccination Sales Market Share by Manufacturer in 2021
Figure 18. Global Varicella Attenuated Live Vaccination Revenue Market Share by Manufacturer in 2021
Figure 19. Varicella Attenuated Live Vaccination Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Varicella Attenuated Live Vaccination Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Varicella Attenuated Live Vaccination Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Varicella Attenuated Live Vaccination Sales Market Share by Region (2017-2028)
Figure 23. Global Varicella Attenuated Live Vaccination Revenue Market Share by Region (2017-2028)
Figure 24. North America Varicella Attenuated Live Vaccination Revenue (2017-2028) & (USD Million)
Figure 25. Europe Varicella Attenuated Live Vaccination Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Varicella Attenuated Live Vaccination Revenue (2017-2028) & (USD Million)
Figure 27. South America Varicella Attenuated Live Vaccination Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Varicella Attenuated Live Vaccination Revenue (2017-2028) & (USD Million)
Figure 29. Global Varicella Attenuated Live Vaccination Sales Market Share by Type (2017-2028)
Figure 30. Global Varicella Attenuated Live Vaccination Revenue Market Share by Type (2017-2028)
Figure 31. Global Varicella Attenuated Live Vaccination Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 33. Global Varicella Attenuated Live Vaccination Revenue Market Share by Application (2017-2028)
Figure 34. Global Varicella Attenuated Live Vaccination Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Varicella Attenuated Live Vaccination Sales Market Share by Type (2017-2028)
Figure 36. North America Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 37. North America Varicella Attenuated Live Vaccination Sales Market Share by Country (2017-2028)
Figure 38. North America Varicella Attenuated Live Vaccination Revenue Market Share by Country (2017-2028)
Figure 39. United States Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Varicella Attenuated Live Vaccination Sales Market Share by Type (2017-2028)
Figure 43. Europe Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 44. Europe Varicella Attenuated Live Vaccination Sales Market Share by Country (2017-2028)
Figure 45. Europe Varicella Attenuated Live Vaccination Revenue Market Share by Country (2017-2028)
Figure 46. Germany Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Varicella Attenuated Live Vaccination Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Varicella Attenuated Live Vaccination Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Varicella Attenuated Live Vaccination Revenue Market Share by Region (2017-2028)
Figure 55. China Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Varicella Attenuated Live Vaccination Sales Market Share by Type (2017-2028)
Figure 62. South America Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 63. South America Varicella Attenuated Live Vaccination Sales Market Share by Country (2017-2028)
Figure 64. South America Varicella Attenuated Live Vaccination Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Varicella Attenuated Live Vaccination Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Varicella Attenuated Live Vaccination Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Varicella Attenuated Live Vaccination Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Varicella Attenuated Live Vaccination Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Varicella Attenuated Live Vaccination Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccination in 2021
Figure 76. Manufacturing Process Analysis of Varicella Attenuated Live Vaccination
Figure 77. Varicella Attenuated Live Vaccination Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 弱毒水痘生ワクチン接種のグローバル市場展望 2023年-2029年：一価ワクチン、混合ワクチン
  • 弱毒生水痘ワクチンのグローバル市場展望 2023年-2029年：一価ワクチン、混合ワクチン
  • 水痘ワクチン接種のグローバル市場展望 2023年-2029年：一価ワクチン、混合ワクチン
  • 世界の水痘ワクチン接種市場2022年：市場規模予測（～2028年）
  • 水痘ウイルス生ワクチンのグローバル市場展望 2023年-2029年：子供、大人
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19686 )"世界の水痘弱毒生ワクチン接種市場2022年：市場規模予測（～2028年）" (英文：Global Varicella Attenuated Live Vaccination Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。